Patients First, Improve The Lives.

Cultivating the humanity and liberty,
Realize the open innovation,
Generate proof-of concept clinical data.

PIPELINE

ABOUT US

Aston Sci. is a clinical stage company, based South Korea.
Aston Sci. strives to innovate the paradigm of drug development
based on the open innovation, in oncology, CNS disease, and geriatric medicine.
Aston Sci. has been focusing on generating compelling proof of concept clinical data of investigational drugs.

Our company strives to innovate the medicine to improve patient’s lives.

PEOPLE

MANAGEMENT

  • Hun Jung, MD. PhD.

    Sr. Clinical Director
    Chief Executive Officer

    Hun Jung, M.D./Ph.D., has served as Chief Executive Officer of Aston Sci., along with sitting on the founder and the Board of Directors, since Oct. 2018. Dr. Jung brings to Aston Sci. more than 19 years of clinical experience, including nearly 9 years in the pharmaceutical industry leading translational research, clinical development, and medical affairs of oncology drug. Dr. Jung founded Aston Sci. with enriched experiences of MSD (Merck & Co.) and Samsung Bioepis. As a clinician of general surgery at Catholic Medical Center and Samsung Medical Center, Dr. Jung conducted preclinical and clinical researches in GI oncology. Prior to that, he was a general surgery resident at College of Medicine, the Catholic University of Korea. Also, he has been continuously contributing his efforts in activities of oncology medical societies.

  • Harry Hunwoo Shin, PhD.

    VP, Chief Business Officer
    Head of R&D center

    Harry Hunwoo Shin,. Before joining Aston Science, Harry served MSD (Merck in USA) for 3 years as business development director to scout and develop business development opportunities for pharmaceutical pipelines sprouting from Korea. Previously, Harry worked at Korea Health Industry Development Institute (KHIDI) for 2.5 years as a exec. consultant to facilitate global licensing deal for Korean companies’ pipelines. Before joining KHIDI, Harry worked at SK Bio-Pharm (NJ/Korea) for 18 years as a medicinal chemist, research program director and business development director.

WORKING TOGETHER WITH

  • Eunkyo Joung, MD.

    Clinical Director

  • Jiyun Lee, MPH.

    Clinical Project Director

  • Minji Yu

    Clinical Project Manager

  • Eunsun Kwon

    Business Development Director

  • Jung Yim

    Executive Administrator

  • Ashley Youngmin Kim

    External Project Manager

  • Byungmin Kim

    Company Operation Director

  • Hyohyun Park, PhD.

    Principal Research Scientist

BOARD OF DIRECTOR

  • Hun Jung, MD

  • Harry Shin, PhD

  • HaeMyoung Jeon, MD

  • MinSeop Song

FOUNDERS

  • Hun Jung, MD

  • Harry Shin, PhD

  • Jihyun Kim, MD

  • Cwangkwang Chung

  • Ilboo Kim

  • Yeojin Jung

BUSINESS MODEL

CAPABILITY

PIPELINE

NEWS

제3자배정 유상증자 신주발행 공고(일정변경)

작성자
jungyim
작성일
2020-10-26 11:54
조회
20570
제3자배정 유상증자 신주발행 공고(일정변경)[2020.10.26]

 

당사는 2020. 10. 12.자 이사회에서 신주의 발행을 결의하였으나, 업무 협의과정에서 불가피하게 일부 일정의 변경이 발생하였습니다.

이에 2020. 10. 26. 이사회결의를 거쳐 상법 제418조 제4항에 따라 이를 공고합니다.

 

 

2020. 10. 26

주식회사  애스톤사이언스

대표이사 정헌

PARTNERS

We are building our value with partners that share vision and culture to improving humanity.

CONTACT

본사(서울)

부설연구소(광교)

ADDRESS
㈜ 애스톤사이언스 본사 (HQ, Seoul Office)
[06193] 서울시 강남구 선릉로 90길 40, 10층 (藝感빌딩)

㈜ 애스톤사이언스 부설연구소 (R&D Facility)
[16506] 수원시 영통구 광교로 156, 1510호 (광교비즈니스센터)

TEL : 02-2038-2347

법인설립 : 2018. 10. (since 2018)
법인등록번호 : 110111-6876423
사업자등록번호 : 354-88-01258
벤처기업인증번호 : 20190300687 (2019. 07.)

(주)애스톤사이언스는 개인정보보호법을 준수합니다.

NAME

E-MAIL ADDRESS

COMMENTS